About me
Dr. Ángel Cebolla is a scientist and serial bioentrepreneur with more than 25 years of experience translating academic research into profitable biotech solutions. After founding Biomedal and leading its world-class rapid food diagnostics division to a successful exit with the US multinational Hygiena, Dr. Cebolla became CEO of ONESTX. This company is currently seeking a €5M Series A lead investor to advance LON-21, a de-risked therapy with a novel mechanism of action for age-related neurodegenerative diseases, into Phase IIa clinical trials.
